About this episode

This episode discusses the FDA-approved VMAT2 inhibitors Valbenazine and Deutetrabenazine for treating tardive dyskinesia.

Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo). References: https://pubmed.ncbi.nlm.nih.gov/41626799/ https://www.ncbi.nlm.nih.gov/books/NBK548187/ https://pubmed.ncbi.nlm.nih.gov/41626799/

People in this episode

Hosts: Dr. Tanner Hewitt, Dr. Larry Wang, Dr. Bradley Miller

Topics covered

• tardive dyskinesia
• VMAT2 inhibitors
• psychiatry
• medication
• healthcare

Keywords

• tardive dyskinesia
• VMAT2 inhibitors
• Valbenazine
• Deutetrabenazine
• FDA-approved medications

Mentioned in this episode

Organizations: FDA, PubMed, NCBI

Products: Valbenazine (Ingrezza), Deutetrabenazine (Austedo)

More episodes of PsychRounds: The Psychiatry Podcast

• Amantadine (Symmetrel) · April 8, 2026 · 17 min
• A DSM Conversation with Dr. Allen Frances · February 25, 2026 · 56 min
• Topiramate (Topamax) · January 28, 2026 · 15 min
• What Makes Something a Psychiatric Illness? Featuring Dr. Mark Ruffalo, MSW, DPsa · January 14, 2026 · 55 min
• Lorazepam (Ativan) · December 31, 2025 · 14 min
• The Vitamin Series: Iron Deficiency in Psychiatry · December 17, 2025 · 25 min

Explore listener stats, chart rankings, contacts and more on the PsychRounds: The Psychiatry Podcast podcast page.